Exacerbation of atherosclerosis by hypertension potential mechanisms and clinical implications

Archives of Internal Medicine

Volumn 156, Issue 17, 1996, Pages 1952-1956

  Chobanian, Aram V ^a   Alexander, R Wayne ^b  

^a BOSTON UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; ARTERIOSCLEROSIS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION;

EID: 0029794137     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.17.1952     Document Type: Review

References (54)

1. Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest. 1968;18:538-551.
2. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. Epidemiology and Control of Hypertension. New York, NY: Thieme-Stratton Inc; 1975:553-592.
3. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. JAMA. 1990;264:354-358.
4. Working Group on Management of Patients With Hypertension and High Blood Cholesterol. National Educational Program Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med. 1991;114:224-237.
5. Chobanian AV. Corcoran Lecture 1989: adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension. 1990;15:666-674.
6. Chobanian AV, Lichtenstein AH, Nilakhe V, Haudenschild CC, Drago R, Nickerson C. Influence of hypertension on aortic atherosclerosis in the Watanabe rabbit. Hypertension. 1989;14: 203-209.
7. Sarzani R, Brecher P, Chobanian AV. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest. 1989;83:1404-1408.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362: 801-809.
9. Li H, Freeman MW, Libby P. Regulation of smooth muscle cell scavenger receptor expression In vivo by atherogenic diets and in vitro by cytokines. J Clin Invest. 1995;95:122-133.
10. Alexander RW. Theodore Cooper Memorial Lecture: hypertension and the pathogenesis of atherosclerosis. Hypertension. 1995;25:155-161.
11. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary-induced atherogenesis in swine: morphology of the intima in prelesion stages. Am J Pathol. 1979;95:775-792.
12. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991; 251:788-791.
13. Marui N, Offerman M, Swerlick R, et al. Vascular cell-adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92: 1866-1874.
14. Parthasarathy S, Quinn MT, Schwenke DC, Carew TE, Steinberg D. Oxidative modification of β-very-low-density lipoprotein: potential role in monocyte recruitment and foam cell formation. Arteriosclerosis. 1989;9:398-404.
15. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
16. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
17. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
18. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288:373-376.
19. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endolhelium-derived relaxing factor. Nature. 1987;327:524-526.
20. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332: 481-487.
21. Crawford DW, Blankenhorn DH. Arterial wall oxygenation, oxyradicals, and atherosclerosis. Atherosclerosis. 1991;89:97-108.
22. Wilson SK. Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat. Circ Res. 1990;66:722-734.
23. Haudenschild CC, Prescott MF, Chobanian AV. Aortic endothelial and subendothelial cells in experimental hypertension and aging. Hypertension. 1981;3(suppl 1):148-153.
24. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
25. Haudenschild C, Prescott MF, Chobanian AV. Effects of hypertension and ils reversal on aortic intimai lesions of the rat. Hypertension. 1980; 2:33-44.
26. Pick R, Prabhu R, Glick G. Diet-induced atherosclerosis and experimental hypertension in stumptail macaques (Macaca arctoides) effects of antihypertensive drugs and a nonatherogenic diet in the evolution of lesions. Atherosclerosis. 1978; 29:405-429.
27. Hollander W, Prusty S, Kirkpatrick PJ, Nagraj S. Role of hypertension in ischemic heart disease in the cynomolgus monkey with coarctation of the aorta. Circ Res. 1977;40(suppl 1):70-83.
28. Xu C, Glagov S, Zatin MA, Zarins CK. Hypertension sustains plaque progression despite reduction in hypercholesterolemia. Hypertension. 1991; 18:123-129.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, II: shortterm reductions in blood pressure, overview of randomised drug trials in their epidemiological context. Lancet. 1990,335:827-830.
30. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA. 1991;265:3255-3264.
31. Chobanian AV. Can antihypertensive drugs reduce atherosclerosis and its clinical complications? Am J Hypertens. 1994;7(suppl):119-125.
32. Kramsch DM, Sharma RC. Limits of lipid lowering therapy: the benefits of amlodipine as an antiatherosclerotic agent. J Hum Hypertens. 1995; 9(suppl 1):53-59.
33. Lichtlen PR, Hugenholtz P, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
34. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82: 1940-1953.
35. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
36. Himeno H, Crawford DM, Mosoi M, Chobanian AV, Brecher P. Angiotensin II alters fibronectin independent of hypertension. Hypertension. 1994; 23:823-826.
37. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
38. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
39. Bath PMW, Hassal DG, Gladwin AM, Palmer RMJ, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscl Thromb Vase Biol. 1991;11:254-260.
40. Lütscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395-418.
41. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
42. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide accelerates neointima foam cell accumulation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb Vase Biol. 1994;14: 753-759.
43. Schuh JR, Blehmn DJ, Friedrich GE, McMahon EG, Blaine EH. Differential effects of reninangiotensin blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest. 1993;91:1453-1458.
44. Rakugi H, Kim D-K, Kreger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin-converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93:339-346.
45. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hypertipidemic rabbit. Hypertension. 1990;15:327-331.
46. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
47. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
48. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
49. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-691.
50. Van der Wal AC, Becker AE, van der Loos CM, Das P. Site of intimai erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89: 503-505.
51. Fuster V, Lewis A. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146. Conner Memorial Lecture.
52. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms, oxidation, inflammation, and genetics. Circulation. 1995;91: 2488-2496.
53. Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation. 1994; 89:503-505.
54. Mancini GBJ, Henry GC, Kubaner Ml, Wargovich TJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study (Trial on Reversing ENdothelial Dysfunction). J Am Coll Cardiol. 1996;27:19. Abstract.